Goldman Sachs Backs Abivax With Buy Rating and $155 Price Target

Goldman Sachs has initiated coverage of Abivax's stock with a buy rating and a price target of $155.00, according to a recent report.

The firm's positive view centers on the company's pipeline asset obefazimod, which has completed Phase 3 trials for ulcerative colitis.

Goldman Sachs views the clinical profile as de-risked with potential to address unmet needs in ulcerative colitis despite a competitive market.

The firm models peak sales of €4 billion for obefazimod in ulcerative colitis, primarily in the second-line and later treatment settings, and sees €3.5 billion in revenue potential for the drug in Crohn's disease, where Phase 2b data is expected in mid-2027.